ChemoCentryx Posts Favorable PK, PD Results Of Oral PD-L1 Inhibitor In Cancer
ChemoCentryx Inc (NASDAQ:CCXI) announced the presentation of preclinical data and initial pharmacokinetic (PK) and pharmacodynamic (PD) data from the ongoing Phase…
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
ChemoCentryx’s Return On Capital Employed Insights
ChemoCentryx (NASDAQ:CCXI) brought in sales totaling $2.31 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 81.68%, resulting in a loss of $40.53 million.
68 Biggest Movers From Yesterday
Gainers
ECMOHO Limited (NASDAQ: MOHO) climbed 56.7% to close at $0.3650 on Wednesday after jumping 10% on Tuesday.
See Why Is Stifel Analyst ‘Perplexed’ After ChemoCentryx Q4 Earnings
Stifel has reiterated a Buy rating and $85 price target on ChemoCentryx Inc (NASDAQ:CCXI) following the Q4 results. Analyst Dae Gon Ha says…
41 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
ECMOHO Limited (NASDAQ: MOHO) jumped 67% to $0.3890 after jumping 10% on Tuesday.
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the holiday-shortened week before making a comeback.
Is Now The Time To Buy Stock In ChemoCentryx, Ideanomics Or Snowflake?
Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders.
Analysts arrive at stock ratings by researching public financial statements, communicating with executives and customers and following industry trends.
Why ChemoCentryx Shares Are Rising
ChemoCentryx Inc (NASDAQ: CCXI) shares are trading higher after the company announced EU approval of TAVNEOS for the treatment of ANCA-associated vasculitis.